{
    "root": "352ed2e2-c7bd-ae21-e063-6394a90ad835",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atorvastatin Calcium",
    "value": "20250515",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "CALCIUM CARBONATE",
            "code": "H0G9379FGK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (110000 WAMW)",
            "code": "5Y0974F5PW"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "ATORVASTATIN CALCIUM TRIHYDRATE",
            "code": "48A5M73Z4Q"
        }
    ],
    "indications": "Atorvastatin calcium is indicated:\n                  \n                     To reduce the risk of:\n                  \n                  \n                     Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD\n                     MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD\n                     Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD\n                  \n                  \n                     As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:\n                  \n                  \n                     Adults with primary hyperlipidemia.\n                     Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                  \n                  \n                     As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).\n                  \n                  \n                     As an adjunct to diet for the treatment of adults with:\n                  \n                  \n                     Primary dysbetalipoproteinemia\n                     Hypertriglyceridemia",
    "contraindications": "Take orally once daily with or without food ( 2.1 ). Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin calcium, and adjust dosage if necessary ( 2.1 ). Adults ( 2.2 ): Recommended starting dosage is 10 or 20 mg once daily; dosage range is 10 mg to 80 mg once daily. Patients requiring LDL-C reduction >45% may start at 40 mg once daily. Pediatric Patients Aged 10 Years of Age and Older with HeFH: Recommended starting dosage is 10 mg once daily; dosage range is 10 to 20 mg once daily ( 2.3 ). Pediatric Patients Aged 10 Years of Age and Older with HoFH: Recommended starting dosage is 10 to 20 mg once daily; dosage range is 10 to 80 mg once daily ( 2.4 ). See full prescribing information for atorvastatin calcium dosage modifications due to drug interactions ( 2.5 ).",
    "warningsAndPrecautions": "Atorvastatin Calcium Tablets, USP are supplied as follows:\n                  \n                  10 mg: White elliptical shaped, film coated tablets, debossed with '10' on one side and 'ATS' on other side.\n                  Bottle of 20 NDC 76420-943-20 (repackaged from NDC 67877-511-XX)\n                  Bottle of 30 NDC 76420-943-30 (repackaged from NDC 67877-511-XX)\n                  Bottle of 60 NDC 76420-943-60 (repackaged from NDC 67877-511-XX)\n                  Bottle of 90 NDC 76420-943-90 (relabeled from NDC 67877-511-90)\n                  Bottle of 120 NDC 76420-943-12 (repackaged from NDC 67877-511-XX)\n                  Bottle of 500 NDC 76420-943-05 (relabeled from NDC 67877-511-05)\n                  Bottle of 1000 NDC 76420-943-00 (relabeled from NDC 67877-511-10)\n                  Bottle of 5000 NDC 76420-943-55 (relabeled from NDC 67877-511-55)\n                  Carton of 100 (10 x 10 unit-dose) tablets NDC 76420-943-38 (relabeled from NDC 67877-511-38)\n                  \n                  20 mg: White elliptical shaped, film coated tablets, debossed with '20' on one side and 'ATS' on other side.\n                  Bottle of 20 NDC 76420-945-20 (repackaged from NDC 67877-512-XX)\n                  Bottle of 30 NDC 76420-945-30 (repackaged from NDC 67877-512-XX)\n                  Bottle of 60 NDC 76420-945-60 (repackaged from NDC 67877-512-XX)\n                  Bottle of 90 NDC 76420-945-90 (relabeled/repackaged from NDC 67877-512-90)\n                  Bottle of 120 NDC 76420-945-12 (repackaged from NDC 67877-512-XX)\n                  Bottle of 500 NDC 76420-945-05 (relabeled from NDC 67877-512-05)\n                  Bottle of 1000 NDC 76420-945-00 (relabeled from NDC 67877-512-10)\n                  Bottle of 4000 NDC 76420-945-44 (relabeled from NDC 67877-512-44)\n                  Carton of 100 (10 x 10 unit-dose) tablets NDC 76420-945-38 (relabeled from NDC 67877-512-38)\n                  \n                  40 mg: White elliptical shaped, film coated tablets, debossed with '40' on one side and 'ATS' on other side.\n                  Bottle of 20 NDC 76420-946-20 (repackaged from NDC 67877-513-XX)\n                  Bottle of 30 NDC 76420-946-30 (repackaged from NDC 67877-513-XX)\n                  Bottle of 60 NDC 76420-946-60 (repackaged from NDC 67877-513-XX)\n                  Bottle of 90 NDC 76420-946-90 (relabeled from NDC 67877-513-90)\n                  Bottle of 120 NDC 76420-946-12 (repackaged from NDC 67877-513-XX)\n                  Bottle of 500 NDC 76420-946-05 (relabeled from NDC 67877-513-05)\n                  Bottle of 1000 NDC 76420-946-00 (relabeled from NDC 67877-513-10)\n                  Bottle of 2000 NDC 76420-946-23 (relabeled from NDC 67877-513-23)\n                  Carton of 100 (10 x 10 unit-dose) tablets NDC 76420-946-38 (relabeled from NDC 67877-513-38)\n                  \n                  80 mg: White elliptical shaped, film coated tablets, debossed with '80' on one side and 'ATS' on other side.\n                  Bottle of 20 NDC 76420-948-20 (repackaged from NDC 67877-514-XX)\n                  Bottle of 30 NDC 76420-948-30 (repackaged from NDC 67877-514-XX)\n                  Bottle of 60 NDC 76420-948-60 (repackaged from NDC 67877-514-XX)\n                  Bottle of 90 NDC 76420-948-90 (relabeled from NDC 67877-514-90)\n                  Bottle of 120 NDC 76420-948-12 (repackaged from NDC 67877-514-XX)\n                  Bottle of 500 NDC 76420-948-05 (relabeled from NDC 67877-514-05)\n                  Bottle of 1000 NDC 76420-948-00 (relabeled from NDC 67877-514-10)\n                  Carton of 100 (10 x 10 unit-dose) tablets NDC 76420-948-38 (relabeled from NDC 67877-514-38)\n                  \n                  \n                     Storage\n                  \n                  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].",
    "adverseReactions": "Acute liver failure or decompensated cirrhosis\n  \n   [see Warnings and Precautions (\n   \n    5.3)]\n  \n   \n                     \n                     Hypersensitivity to atorvastatin or any excipients in atorvastatin calcium. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported\n  \n   [see Adverse Reactions (\n   \n    6.2)]."
}